CanWell will attend ADC & Novel Conjugates Partnering & Investment Summit (September 9-10, 2025)
CanWell Pharma will update company’s ADC programs at ADC & Novel Conjugates Partnering & Investment Summit held on September 9-10, 2025 in Boston. It covers newest research updates on StarLinker dual/tri-payload ADCs, which had been making tremendous progress in preclinical efficacy studies …
CanWell Pharma will Present Research Developments at The Society for Immunotherapy of Cancer (SITC) Annual Meeting
CanWell Pharma will present the latest research developments at the 39th of The Society for Immunotherapy of Cancer (SITC) Annual Meeting held on Nov6-10, 2024 in Houston, TX. The research developments are from its two different studies and will be conducted on the following two posters: Date: Nov8,…
CanWell Pharma will Present Latest Research Developments at World ADC 2024 in San Diego, CA
CanWell Pharma will present its latest research developments at the 15th World ADC in San Diego, CA held on Nov 5-7, 2024. The presentation will be conducted on a poster during Poster Session of the conference. The poster covers newest research updates on Dual-Payload ADCs, which may make significan…
Nature Biopharma Dealmakers Publishes CanWell’s StarLinker ADC conjugation platform
Read More (click to read the original article)
CanWell Pharma’s First-in-Class innovative drug CAN2109 granted IND approval by China National Medical Products Administration (NMPA)
CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted IND approval by the China National Medical Products Administration (NMPA). CanWell plans to immediately initiate the patient enrollment to evaluate CAN2109’s safety, PK, PD and clinical activity for the treat…
CanWell’s CAN2109 IND Granted Approval by US FDA
CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted clinical approval by the US Food and Drug Administration (FDA) and it will soon conduct Phase I clinical trial for various solid tumors. CAN2109 is a novel long-acting Immunogenic cell death (ICD) inducer, whi…
Canwell to Present CAN1012 Research Update at the 4th STING & TLR Targeting Therapies Summit
CanWell announced today that the preclinical research results and clinical plan of the company’s TLR7 agonist CAN1012 would be presented at the 4th STING & TLR Targeted Therapy Summit in 2023. CAN1012 is a highly selective small-molecule TLR7 agonist developed by CanWell with global intell…
CanWell was Invited to Present at 9th Immuno-oncology 360° (IO360°) Conference
CanWell presented the preclinical research results of CAN1012, a small molecule TLR7 agonist in the form of an oral presentation at the 9th Immuno-oncology 360° (IO360°) conference. The IO360° conference is a globally renowned annual conference for cancer immunotherapy, providing a collaboration opp…